Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)

Immunization for EAE decreased the counts of CD4+ and CD8+ T-PBLs in DA rats. by Mirjana Nacka-Aleksić (3342095)

Oral UOX decreased SUA (A), BUN (B) and Cr (C) (mean ± SD, n = 10). by Yu Yun (4710340)

Overexpression of PLIC-1 decreased Trif abundance in a Nocodazole-sensitive manner. by Nabanita Biswas (349647)

Effects of siRNA TMPRSS2-ERG III and IV on cell death pathways. by Giorgia Urbinati (554921)

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository by Fidéline Bonnet-Serrano (4782546)

“…Results were expressed as mean ±SD.</p><p>Results</p><p>An automated quantification method was set up using the R software and was validated by quantification of β-cell mass, a well characterized parameter. β-cell mass was 29.6±112 mg in patients and 628 ±717 mg in controls (p<0.0001). α-cell mass was 181±176 mg in patients and 349 ±241mg in controls (p<0.0001). …”

Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

“…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”

Increased levels of PPARγ and decreased levels of adiponectin in thymus from rats administered cocaine for 7 days. by Kana Unuma (283272)

Subjects:

SRC-3 treatment decreased tumor growth in a Jeko-1 ibrutinib resistant mouse model. by Imani Bijou (18275174)

FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

“…When tumors reached an average of 150 mm³, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”

Calyculin A-induced decrease of tyrosine-monophosphorylated ERK2 at high cell density. by Noriyuki Kawabata (3391739)

Decreased miR-29b/c in GC tissue samples. by He Cui (229445)

Impaired Ubr5 function results in increased canonical and decreased non-canonical HH signalling. by David Mellis (2833469)

Treatment with con-G showed improved neurological scoring and decreased peri-infarct Ca²⁺ microdeposits. by Rashna Balsara (714796)

U87MG glioma cells transduced with gal-3 shRNA demonstrate decreased tumor size and growth. by Rafael Yamashita Ikemori (698128)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

The 599 peptide-mediated silencing of CIP2A decreases oral cancer cell invasiveness and anchorage-independent growth. by Liliana Cantini (453377)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”

VGB decreased activation of the mTOR pathway in vivo. by Bo Zhang (6559)